• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Articles published by Athira Pharma, Inc.

    Athira Pharma to Present Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Meeting
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Tickers ATHA
    Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Tickers ATHA
    Athira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer’s Disease
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Tickers ATHA
    Athira Pharma Reports Second Quarter 2024 Financial Results and Pipeline and Business Updates
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Tickers ATHA
    Athira Pharma Presents Preclinical Data Demonstrating New Insights into the Mechanism by Which Fosgonimeton Protects Neurons from Alzheimer’s Disease-Related Pathology at the Alzheimer’s Association International Conference (AAIC) 2024
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Tickers ATHA
    Athira Pharma Announces Last Patient Completed LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Tickers ATHA
    Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer’s Disease Patients
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Tickers ATHA
    Athira Pharma Completes First Cohort in Phase 1 Clinical Trial of ATH-1105, an Oral, Small Molecule Drug Candidate for Amyotrophic Lateral Sclerosis (ALS)
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Tickers ATHA
    Athira Pharma to Participate in Upcoming June Conferences
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Tickers ATHA
    Athira Pharma Announces Proposed Settlement of Stockholder Derivative Action
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Tickers ATHA
    Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Tickers ATHA
    Athira Pharma to Participate in Upcoming May Conferences
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Tickers ATHA
    Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Tickers ATHA
    Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s Disease
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Tickers ATHA
    Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Tickers ATHA
    Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2024 International Conference
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Tickers ATHA
    Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Tickers ATHA
    Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Tickers ATHA
    Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Tickers ATHA
    Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Tickers ATHA
    Athira Pharma Announces Encouraging Results from SHAPE Phase 2 Clinical Trial of Fosgonimeton for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy Bodies
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Tickers ATHA
    Athira Pharma to Participate in Sidoti December Small Cap Investor Conference
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Tickers ATHA
    Athira Pharma Announces Upcoming Presentation at Motor Neurone Disease Association’s 34ᵗʰ International Symposium on ALS/MND
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Tickers ATHA
    Athira Pharma Presents Preclinical Data Highlighting Fosgonimeton’s Neuroprotective Effects Against Amyloid-β-Induced Pathological Alterations and Neuroinflammation in Models of Alzheimer’s Disease
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Tickers ATHA
    Athira Pharma Reports Third Quarter 2023 Financial Results and Pipeline and Business Updates
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Tickers ATHA
    Athira Pharma to Participate in Jefferies London Healthcare Conference
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Tickers ATHA
    Athira Pharma Presents Preclinical Data Further Supporting the Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Tickers ATHA
    Athira Pharma to Participate in Upcoming October Conferences
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Tickers ATHA
    Athira Pharma to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Tickers ATHA
    Athira Pharma Reports Second Quarter 2023 Financial Results and Pipeline and Business Updates
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Tickers ATHA
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.